Open AccessThe broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies
Author(s) -
Elad Sharon,
Yarom Noam,
Zadik Yehuda,
KutenShorrer Michal,
Sonis Stephen T.
Publication year - 2021
Publication title -
ca: a cancer journal for clinicians
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 62.937
H-Index - 168
eISSN - 1542-4863
pISSN - 0007-9235
DOI - 10.3322/caac.21704
Subject(s) - mucositis , medicine , cancer , quality of life (healthcare) , cancer therapy , intensive care medicine , complication , gastroenterology , oncology , toxicity , nursing
Oral mucositis (OM) is a common, highly symptomatic complication of cancer therapy that affects patients' function, quality of life, and ability to tolerate treatment. In certain patients with cancer, OM is associated with increased mortality. Research on the management of OM is ongoing. Oral mucosal toxicities are also reported in targeted and immune checkpoint inhibitor therapies. The objective of this article is to present current knowledge about the epidemiology, pathogenesis, assessment, risk prediction, and current and developing intervention strategies for OM and other ulcerative mucosal toxicities caused by both conventional and evolving forms of cancer therapy.